Treatment of mice with metastatic NT2.5 tumours with 19.2 MBq of [213Bi]Bi-CHX-A′′-DTPA-anti-HER2-liposomes improved the median survival to 38 d versus 29 d for untreated mice and 27 d for mice treated with unlabeled liposomes. Here, ERBB2 is linked to neoplasm.